Zygomycosis and diabetes mellitus

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 5, 2009, Pages 21-25

  Lanternier, F ^a   Lortholary, O ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Acidosis; Diabetes; Liposomal amphotericin B; Sinusitis; Surgery; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CORTICOSTEROID; DEFERASIROX; DEFERIPRONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; VORICONAZOLE;

BRAIN INFECTION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; GLYCEMIC CONTROL; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; IRON CHELATION; MORTALITY; MUCORMYCOSIS; MYCOCLADUS CORYMBIFER; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHIZOPUS ORYZAE; SINUSITIS; SURVIVAL RATE; ZYGOMYCETES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DIABETES COMPLICATIONS; HUMANS; SINUSITIS; ZYGOMYCOSIS;

EID: 70349980693     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02975.x     Document Type: Review

References (50)

1. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004, 17:517-525.
2. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000, 13:236-301.
3. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556.
4. Roden MM, Zaoutis TE, Buchanan WL. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634.
5. Lechevalier P, Hermoso DG, Carol A. Molecular diagnosis of Saksenaea vasiformis cutaneous infection after scorpion sting in an immunocompetent adolescent. J Clin Microbiol 2008, 46:3169.
6. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004, 350:950.
7. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004, 10(suppl 1):31.
8. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000, 30:851.
9. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584.
10. Ludvigsson J. Why diabetes incidence increases-a unifying theory. Ann NY Acad Sci 2006, 1079:374.
11. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 2007, 44:1089.
12. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006, 50:96.
13. Lukacs G, Papp T, Nyilasi I, Nagy E, Vagvolgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 2004, 42:5400.
14. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399.
15. Bitar D, Van Cauteron D, Lanternier F. Increasing incidence of zygomycosis (mucormycosis) Metropolitan France, 1997-2006. Emerg Infect Dis 2009, 15.
16. Zaoutis TE, Roilides E, Chiou CC. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007, 26:723.
17. Chakrabarti A, Das A, Mandal J. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006, 44:335.
18. Reed C, Bryant R, Ibrahim AS. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364.
19. Kontoyiannis DP, Lionakis MS, Lewis RE. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350.
20. Singh N, Aguado JM, Bonatti AJ. Zygomycosis in solid organ transplant recipients: a prospective, case-controlled study to assess risks for disease and outcome. J Infect Dis 2009
21. Calvet HM, Yoshikawa TT. Infections in diabetes. Infect Dis Clin North Am 2001, 15:407.
22. Gale GR, Welch AM. Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum. Am J Med Sci 1961, 241:604.
23. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984, 74:150.
24. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999, 341:1906.
25. Sheldon WH, Bauer H. The development of the acute inflammatory response to experimental cutaneous mucormycosis in normal and diabetic rabbits. J Exp Med 1959, 110:845.
26. Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982, 38:1123.
27. Rosenbloom AL. Hyperglycemic crises and their complications in children. J Pediatr Endocrinol Metab 2007, 20:5.
28. McNulty JS. Rhinocerebral mucormycosis: predisposing factors. Laryngoscope 1982, 92(10 Pt 1).
29. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007, 45:321.
30. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003, 47:3343.
31. Ibrahim AS, Gebremariam T, Husseiny MI. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008, 52:1573.
32. Ibrahim AS, Bowman JC, Avanessian V. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005, 49:721.
33. Spellberg B, Fu Y, Edwards JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005, 49:830.
34. Ibrahim AS, Edwards JE, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006, 58:1070.
35. Ibrahim AS, Gebermariam T, Fu Y. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649.
36. Reed C, Ibrahim A, Edwards JE, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968.
37. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003, 51:45.
38. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003, 47:3647.
39. Greenberg RN, Mullane K, van Burik JA. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126.
40. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61.
41. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005, 5:775-785.
42. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004, 58:612.
43. Nosari A, Oreste P, Montillo M. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica 2000, 85:1068.
44. Walsh TJ, Hiemenz JW, Siebel NL. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26:1383-1396.
45. Herbrecht R, Letscher-Bru V, Bowden RA. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001, 20:460.
46. Groll AH, Giri N, Petraitis V. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274.
47. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503.
48. Walsh TJ, Goodman JL, Pappas P. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001, 45:3487.
49. Bjorkholm M, Runarsson G, Celsing F, Kalin M, Petrini B, Engervall P. Liposomal amphotericin B and surgery in the successful treatment of invasive pulmonary mucormycosis in a patient with acute T-lymphoblastic leukemia. Scand J Infect Dis 2001, 33:316.
50. Parkyn T, McNinch AW, Riordan T, Mott M. Zygomycosis in relapsed acute leukaemia. J Infect 2000, 41:265.